Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma
A single-arm, open-label early-stage exploratory clinical study to evaluate the safety, tolerability and efficacy of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in subjects with gastric/gastroesophageal junction adenocarcinoma.
Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
DRUG: Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection
Occurrence of Dose limiting toxicity., Occurrence of DLTs (Dose limiting toxicity)., Within 28 days after the first infusion|Incidence of treatment-emergent AEs, AESIs, and SAEs., Incidence of treatment-emergent AEs, AESIs, and SAEs., 48 weeks
Disease control rate (DCR), The proportion of participants who have a confirmed CR, confirmed PR, or who have SD per RECIST v1.1 as assessed by the investigator at local site and derived from the raw tumor data for at least 11 weeks after infusion date., 12 months|Objective response rate (ORR), The proportion of participants who have a confirmed CR or confirmed PR as determined by the investigator at local site per RECIST v1.1., 12 months|Duration of disease control (DDC), The period from the first evaluation of CR, PR or SD to the first evaluation of PD or any cause of death., 12 months|Duration of response (DOR), The period from the first evaluation of CR or PR to the first evaluation of PD or death of any cause., 12 months|Progression-free survival (PFS), The period from the first cells infusion to the first recorded tumor progression or death of any cause., 12 months|Overall survival (OS), The period from the first cells infusion to death of any cause., 12 months|Proliferation and persistence of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell, Proliferation and persistence of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection in peripheral blood after infusion detected by Quantitative Real-time PCR (qPCR) and Flow Cytometry (FCM)., 12 months|Incidence of anti-CAR-T cell antibody in peripheral blood after infusion., Incidence of anti-CAR-T cell antibody in peripheral blood after infusion., 12 months
This study is an open-label, single-/multiple-dose infusion, adaptive dose-escalation designed early exploratory clinical trial aiming to evaluate the safety, tolerability, and efficacy of Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection in subjects with CLDN18.2 positive and pathologically confirmed locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma.